Background-The value of prehospital initiation of glycoprotein IIb/IIIa inhibitors remains a controversial issue. We sought to investigate whether in-ambulance initiation of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) improves ST-segment elevation resolution (STR) after primary percutaneous coronary intervention (PCI).
T he major goal of reperfusion strategies in acute ST-segment elevation myocardial infarction (STEMI) is to limit infarct size and improve outcomes. Although primary percutaneous coronary intervention (PCI) with stenting leads to restoration of normal epicardial perfusion in Ͼ90% of patients, 1 damage to the microvascular circulation occurs in 30% to 50% of cases. 2 In these circumstances, the failure to restore capillary flow leads to an increase in lesion development and is associated with high mortality. 2, 3 STsegment elevation resolution (STR) is an indicator of microvascular circulation and a strong prognostic factor following reperfusion after thrombolysis 4 or primary PCI. 5 Similarly, a complete STR is associated with a significant decrease in myocardial infarct size and preservation of left ventricular ejection fraction (LVEF). 5 By rapidly and potently preventing platelet activation, the glycoprotein (GP) IIb/IIIa inhibitor abciximab has great potential for reducing microvascular damage after primary PCI. In turn, facilitation of primary PCI by GP IIb/IIIa inhibitors increases Thrombolysis In Myocardial Infarction (TIMI) 2 to 3 flow rates before PCI (ADMIRAL [Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up] study). 6, 7 Current guidelines support the routine use of abciximab in primary PCI for STEMI, 6, 8 especially in high-risk patients. However, the optimal timing of GP IIb/IIIa inhibitor use (ie, in-ambulance versus catheterization laboratory) remains a controversial issue, with positive randomized trials 6, 7 and registry 9 studies on one hand and one large negative randomized clinical trial on the other (the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events [FINESSE] study). 10 The main criticism 11 faced by the FINESSE study was the length of time from onset of symptoms to drug administration (median, 165 minutes) as well as from door to balloon (median, 132 minutes). These delays were considerably longer than in the Ongoing Tirofiban in Myocardial Infarction Evaluation 2 (ON-TIME-2) study that showed benefits of early GP IIb/IIIa inhibitors, with delays of 80 and 76 minutes, respectively, which are more consistent with current guidelines for door-to-balloon time. We designed the Myocardial Infarction with ST-elevation Treated by Primary Percutaneous Intervention Facilitated by Early Reopro Administration in Alsace (MISTRAL) study to investigate the impact of abciximab administration in the ambulance versus in the catheterization laboratory for patients with STEMI promptly and directly admitted to the catheterization laboratory.
WHAT IS KNOWN
• Optimal timing of administration of glycoprotein IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction treated by percutaneous coronary intervention is controversial.
• The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) study investigators recorded no benefit of early versus late abciximab administration, but administration was late.
• However, the ON-TIME-2 (Ongoing Tirofiban in Myocardial Infarction Evaluation 2) study investigators showed that prehospital tirofiban (door-to-balloon time, 76 minutes) in patients with ST-segment elevation myocardial infarction improved ST-segment elevation resolution and Thrombolysis In Myocardial Infarction flow.
WHAT THE STUDY ADDS
• This study demonstrated that early ambulance administration of abciximab in patients with ST-segment elevation myocardial infarction did not improve either ST-segment elevation resolution or Thrombolysis In Myocardial Infarction flow rate after primary percutaneous, but it tended to improve TIMI flow pre-PCI and decreased distal embolization during procedure.
Methods
The MISTRAL study is a prospective, controlled, multicenter, randomized, double-blind, and double-dummy study. 
Study Protocol
Patients were randomly assigned to prehospital treatment with abciximab (0.25 mg/kg IV bolus) or placebo together with 250 mg aspirin IV and 40 IU/kg (maximum dose, 3000 IU) of unfractionated heparin. The randomization done was according to the manufacture of the treatment study kits, which had to be used consecutively. Randomization was stratified by centers. Activated clotting time (ACT) was measured immediately before the procedure in all equipped centers. If the ACT was Ͻ150 s, an additional bolus of 35 IU/kg was given. By contrast, an additional bolus of 25 IU/kg was administered if the ACT was 150 to 199 s (maximal dose, 5000 IU).
A standard 3000-IU bolus was given to patients enrolled in centers unable to measure the ACT. Patients in the placebo group received blinded therapy with abciximab (0.25 mg/kg IV bolus) immediately after angiography and before PCI. After PCI, all patients received a 0.125-g/kg per minute infusion of abciximab for 12 hours. Because at the time of the study design upstream clopidogrel was not considered the standard of care, a 300-or 600-mg loading dose of this drug was given after PCI at the discretion of the physician.
End Points
The primary study end point was STR (expressed as percentage) achieved 60 minutes after PCI, taking into account the sum of ST deviation in all 12 leads. 12 Complete STR was defined when the STR reached 70%. Secondary end points included residual ST-segment elevation (expressed in millimeters); the incidence of major adverse cardiac events (MACEs), including death, nonfatal myocardial infarction, and coronary revascularization, at 30 days and 6 months; TIMI flow before and after PCI; LVEF measured by echocardiography; and enzymatic infarct size.
Electrocardiography
All analyses were performed by an independent electrocardiography core laboratory (Dr Rolf Schröder; Berlin, Germany) on ECGs obtained at patient enrollment in the ambulance (ECG-1), at admission to the catheterization laboratory before angiography (ECG-2), and 60 minutes after PCI (ECG-3). The following parameters were assessed (measured in millimeters): sum of ST-segment elevation, maximal ST elevation measured in the lead with the most prominent ST-segment deviation, sum of ST-segment depression, and maximal ST depression measured in the lead with the most prominent ST depression. The primary end point was the regression of the sum of ST-segment elevation between an ECG obtained before and 60 minutes after PCI. The residual sum of ST-segment elevation on ECG at admission (ECG-2) and after PCI (ECG-3) served as a secondary end point.
Angiograms
All angiograms were reviewed by an independent core laboratory (Angiolap; Creteil, France) to determine TIMI flow, quantitative coronary analysis before and after PCI, slow flow, and distal embolization. Slow flow or no reflow during primary PCI was defined as a TIMI flow grade Ͻ3 not attributable to dissection, and distal embolization was defined as a distal filling defect with an abrupt cutoff in one of the peripheral coronary branches of the infarct-related artery distal to the angioplasty site.
Laboratory Methods
Enzymatic infarct size was estimated by a centralized laboratory (Hôpitaux Universitaires de Strasbourg, France) by measurement of the troponin I level in a single sample taken 6 hours after PCI, as described previously. 13 Additional parameters measured by the centralized laboratory included troponin I at admission and brain natriuretic peptide at admission and at discharge.
Clinical End Points
MACE was defined as a composite of all-cause death, recurrent myocardial infarction, and target vessel revascularization. Evidence of myocardial reinfarction was defined as chest pain or ECG changes accompanied by a reelevation in creatine kinase MB level (Ͼ2 times the upper limit of normal or Ͼ3 times in the case of PCI). Target vessel revascularization was defined as the need for new PCI or coronary artery bypass graft of the culprit vessel because of either symptom recurrence or a positive ischemic functional test at followup. Safety end points were hemorrhages, transfusions, and serious adverse events. Bleeding was classified using the TIMI group classification. 14 Clinical events were adjudicated in a blinded fashion. The treatment kit numbers were unblinded only when the database was closed for both the primary and the secondary end points. Adjudication was performed jointly by both the local investigators and the principal investigator.
Data Analysis
The sample size (nϭ292) was initially calculated to provide 90% power to detect an 18% absolute difference in complete STR.
Because of slower-than-expected enrollment, the protocol was amended in May 2009, and the power was reduced to 83%, yielding a revised sample size of 240 patients. At that time, the investigators had no access to the data and remained blinded to the treatment group. The missing data for the primary end point were excluded from the analysis. Analyses were performed on the basis of the intention-to-treat principle. The study drug allocation was unblinded after finalizing and closing the database. Results are expressed as meanϮSD for continuous, normally distributed variables and medians and interquartile ranges (IQRs) for skewed data. Categorical variables are expressed as frequencies. Continuous variables were compared using the Student t test, and categorical variables were analyzed using the Fisher exact test. The Mann-Whitney test was used for skewed data. Kaplan-Meier analyses were used to construct survival plots of time to MACE and compared using the log-rank test. All tests were 2-sided. All calculations were performed using SPSS version 11.5 statistical software.
Results
A total of 256 consecutive patients (ambulance group, nϭ127; hospital group, nϭ129) were included in the study. The 2 groups had similar baseline clinical and angiographic characteristics ( Table 1 ). The median time ( Figure 1 ) between onset of symptoms and first bolus was 114 minutes (IQR, 80 -190 minutes) and between onset of symptoms and balloon inflation, 195 minutes (IQR, 158 -268 minutes), whereas the median door-to-balloon time was 103 minutes (IQR, 90 -124 minutes). The median time of administration between the first and the second bolus (ie, the time difference between the study groups for the start of drug treatment) was 65 minutes (IQR, 54 -78 minutes). Myocardial infarction was located in the anterior territory in 40% of the patients, and 91% were in Killip class 1. Time delays did not differ significantly between the 2 groups ( Table 2) . ACT measurements at admission (before the second heparin bolus) were available for 37% of the patients and were 147Ϯ34 s in the ambulance group and 147Ϯ31 s in the hospital group.
ECG Analysis
The results of ECG analysis are provided in Table 3 . ECGs were available for analysis in 227 patients at inclusion, 211 patients before angiography, and 239 patients after PCI. No statistically significant differences were evident between the groups in terms of residual ST elevation or complete STR rates. The 18 patients missing the primary outcome did not differ in any substantial way from the patients who had the outcome measured.
Angiographic Analysis
Angiography was performed in all patients and available for core laboratory analysis in 226 participants (Table 4) . Initial TIMI flow rates (Table 5 ) tended to be grade 2 to 3 more frequently in the ambulance group than in the hospital group 
Infarct Size
LVEF was evaluated by echocardiography during the index hospitalization and was similar in both groups (ambulance group, 53.47Ϯ9.75%; hospital group, 52.47Ϯ10.62%). There was no significant differences in biological infarct size between the groups, as estimated by the peak level of troponin I sampled 6 hours after PCI (67.64Ϯ76.88 versus 80.88Ϯ75.43 ng/mL, Pϭ0.18). There were also no statistically significant differences in the peak creatinine kinase levels (2224Ϯ2248 versus 2333Ϯ1894 IU/L, Pϭ0.70), brain natriuretic peptide levels at admission (36.6Ϯ52.26 versus 37.1Ϯ46.5 pg/mL, Pϭ0.94), and brain natriuretic peptide levels at discharge (119.9Ϯ136.6 versus 149.2Ϯ153.4 pg/ mL, Pϭ0.19).
Clinical Outcomes
Five patients were lost to follow-up at 1 month, whereas another 5 were lost at 6 months. Three (1.1%) patients died during hospitalization (1 of cardiac and 1 of noncardiac causes in the ambulance group and 1 of cardiac causes in the hospital group). The occurrence of myocardial infarction and target vessel revascularization rates were low and similar between the study groups at 1 and 6 months ( Table 6) . Kaplan-Meier analysis of MACE-free survival is depicted in Figure 2 . Rates of major bleeding were low (ambulance group, 0.8%; hospital group, 1.6%; Pϭ1).
Discussion
The major findings of the MISTRAL study are as follows: (1) Early in-ambulance administration of abciximab did not improve postprocedural STR and postprocedural TIMI flow rates compared with routine abciximab administration in the catheterization laboratory; (2) there was a tendency toward better preprocedural TIMI 2 to 3 flow and significantly less procedural embolization and slow flow, which taken together, suggest a possible preprocedural therapeutic effect of early ambulance abciximab administration; and (3) early ambulance abciximab administration did not decrease MACE at 30 days and 6 months and did not improve LVEF or biological infarct size.
Impact of Timing on STR and TIMI Flow
To our knowledge, this is the first double-blind study to compare the effects of in-ambulance versus in-catheterization laboratory administration of abciximab on STR after PCI. We failed to demonstrate that in-ambulance administration of abciximab improves STR after PCI. In the FINESSE study, prehospital abciximab alone or together with half-dose lytics (tenecteplase) also failed to demonstrate a beneficial effect on the frequency of MACEs compared to drug administration in the catheterization laboratory. 10 Complete postprocedural STR rates in the FINESSE study (in a subset of 745 patients) were 33.1% in the abciximab group and 31% in the primary PCI group. The quite lower rates of complete STR in the FINESSE compared with the MISTRAL study (70% and 66%, respectively) are indicative of suboptimal myocardial reperfusion and may have resulted from differences in the risk profile of the study populations, longer time delays between symptom onset and drug administration (165 versus 115 minutes), and longer door-to-balloon times (132 versus 103 minutes). The difference in the rate of STR between the studies may also be related to other factors that influence STR, such as the rate of anterior infarction (MISTRAL, 39%; FINESSE, 45%) 15 or the age of the patients (MISTRAL, 58 years; FINESSE, 62 years). 5, 16 The complete postprocedural STR rates in the more-recent ON-TIME-2 study were closer to those seen in MISTRAL and were significantly improved in the prehospital group (65.6% versus 60.0%). 7 However, in the ON-TIME-2 study, only 28% of the patients in the control group received the GP IIb/IIIa inhibitor tirofiban because it was administered provisionally per protocol. This may have contributed to the difference between groups after PCI in ON-TIME-2 study compared with the MISTRAL and FI-NESSE studies, in which all control patients routinely received the study drug in the catheterization laboratory. The investigators in the ON-TIME-2 study 7 were able to achieve very early administration of the GP IIb/IIIa inhibitor, with an interval of just 76 minutes between symptom onset and drug Data are presented as n/n (%), unless otherwise indicated. LAD indicates left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; IQR, interquartile range; BMS, bare-metal stent; DES, drug-eluting stent. 11% in the ON-TIME-2 study (43% versus 38.2% TIMI 2 to 3 flow rates, Pϭ0.069). By contrast, TIMI flow rates at the initial angiogram were not improved by early abciximab in the FINESSE study (14.1% versus 12.0%), which had longer time-to-treatment delays. All together, these observations suggest that very early use of GP IIb/IIIa inhibitors in the first 2 hours (golden hours) after myocardial infarction, as in the ON-TIME-2 study, is crucial to achieving a prehospital increase in culprit artery recanalization before primary PCI. It can be hypothesized that a similar prehospital effect was operative in the current study, but this did not reach statistical significance because of a longer delay from symptom onset to drug administration and, more importantly, to insufficient power. In the MISTRAL and ON-TIME-2 studies, preprocedural administration of a GP IIb/IIIa inhibitor was significantly associated with reduced slow flow and embolization during PCI, which would be expected to lead to improved outcomes. 17 In MISTRAL, however, the effects on slow flow and embolization did not translate into improved final TIMI flow, STR, or MACE, possibly because of the systematic use of abciximab during PCI in the catheterization laboratory group.
Patient Risk
Growing evidence suggests that the benefits of abciximab in STEMI are confined to high-risk patients. Indeed, earlier studies that included low-risk patients, such as the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Combinations) trial, did not show any beneficial effects of abciximab treatment compared with studies that enrolled higher-risk patients, such as the ADMIRAL and ACE (Abciximab and Carbostent Evaluation) trials. 6, 8 A recent meta-analysis focusing on STEMI 18 demonstrated a direct correlation between the benefit of GP IIb/IIIa inhibitors and the risk category of the patients. In addition, a subanalysis of the EUROTRANSFERT registry showed that when patients were stratified by risk category, the entire benefit of abciximab treatment was confined to patients classified as high risk (ie, with a TIMI risk score Ն3 [35% of the patients in this study]). 9 The MISTRAL study included a selected population with a low-risk profile (average age, 58 years; 8% Killip class, Ͼ1; TIMI risk score, Ͼ3 in 17% of the study subjects; diabetes rate, 8%), resulting in a very low mortality rate (1.17%). This low-risk profile might have contributed to the minimal effects observed following early abciximab treatment. The benefit of early aggressive antiplatelet treatment may be reduced by the potential risk of increased bleeding complications. In this study, the rates of bleeding were low and did not differ between the study groups. The young age of the patients together with the radial approach to PCI and low-dose heparin may account for these results. Recent evidence has suggested that heparin administration may reduce the risk of acute stent thrombosis in patients with STEMI treated by bivalirudin monotherapy. 19, 20 However, this protective effect was not observed when GP IIb/IIIa inhibitors were administered with antithrombin drugs. The per-protocol lack of clopidogrel pretreatment might be viewed as a deviation from the standard of care. However, because the time to peak effect with clopidogrel is Ϸ4 hours, a genuine clinical impact is unlikely. The upstream use of new-generation thienopyridines 21, 22 may be more effective and can hamper the clinical relevance of the present study. Although these drugs are helpful in improving clinical outcomes, the evidence supporting their upstream use is still inconclusive. In addition, it remains uncertain whether they can improve tissue perfusion in STEMI. Novel thienopyridines still have a delayed effect 23, 24 compared with the immediate platelet-blocking action of IV GP IIb/IIIa inhibitors. This difference might be particularly relevant for veryhigh-risk patients in whom the oral route may be unsuitable. A recent open-label study has shown that bivalirudin can decrease the risk of bleeding in patients with STEMI. 20 It is noteworthy that the risk of bleeding was very low in the present study population, which may be at least in part due to the use of low-dose heparin. Indeed, the heparin dose regimen was lower in the MISTRAL study than in the GP IIb/IIIa arm of the HORIZON (Harmonizing Outcomes with Revascularization and Stents) trial.
Limitations
The present study has several limitations. Because of the small sample size, the study is underpowered to confirm conclusively the tendencies toward a clinical benefit of very early abciximab treatment. In addition, we used an intermediate marker (STR) as the main end point in this clinical efficacy study. Of note, the study was underpowered for clinical outcome data (MACE and its components), and adjudication was performed jointly by both the local investigators and the principal investigator. The recruitment period was long (5 years), during which time changes in the clinical practice of the participating teams may have occurred. ACT measurements were performed in only 37% of the centers. A second bolus of 3000 IU was administered to only patients enrolled in centers unable to determine the ACT value. For this reason, caution should be exercised in interpreting these findings.
Conclusions
Ambulance administration of abciximab in patients with STEMI undergoing PCI did not improve postprocedural STR, final TIMI flow rate, LVEF, and MACE compared with routine abciximab administration in the catheterization laboratory. However, it tended to improve TIMI 2 to 3 flow rates and significantly reduced distal embolization during the procedure. Abciximab given very early in the course of STEMI might facilitate primary PCI by improving the visibility of the coronary anatomy, thus allowing a faster and more-accurate procedure. Similar studies with an increased sample size should be conducted to confirm these results.
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